• 1
    Linthorst GE, Germain DP, Hollak CE et al. . Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011; 102: 405.
  • 2
    Weidemann F, Niemann M, Stork S et al. Long term Outcome in Advanced Fabry disease under causal enzyme replacement therapy. Evidence for disease progression towards serious complications. J Intern Med 2013; [Epub ahead of print].
  • 3
    Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013; 8: 47.
  • 4
    EI Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2013; 2: CD006663.
  • 5
    Mehta A, Clarke JTR, Giugliani R et al. Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survery. J Med Genet 2009; 46: 54852.
  • 6
    Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009; 11: 7906.
  • 7
    Keslova-Veselikova J, Hulkova H, Dobrovolny R et al. Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Arch 2008; 452: 65165.
  • 8
    Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R. Cellular and issue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007; 90: 30712.
  • 9
    Lidove O, West ML, Pintos-Morell G et al. Effects of enzyme replacement therapy in Fabry disease – A comprehensive review of the medical literature. Genet Med 2010; 12: 66879.
  • 10
    Mehta A, Beck M, Giugliani R et al. Enzyme replacement therapy with agalasidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009; 374: 198696.
  • 11
    Frustaci A, Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation 2007; 116: 3501.
  • 12
    Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alfa and beta. Kidney Int 2004; 66: 158995.
  • 13
    Ben Turkia H, Gonzalez DE, Barton NW et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol, 2013; 88: 17984.
  • 14
    Germain DP, Guigliani R, Hughes DA et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis 2012; 7: 91.
  • 15
    Laurence DR. Clinical Pharmacology, 3rd edn.London: Churchill, 1966.